The International Agency for Research on Cancer (IARC) states that 905,677 new liver cancer cases and 2,206,771 new lung cancer cases were recorded in 2020. Thus, the surging need for effective drug development and discovery, on account of the growing prevalence of chronic heart, lung, liver, kidney, brain, and intestine diseases, will create an extensive requirement for organ-on-chip products globally.

In addition, the increasing amount of government grants and funds being provided for research in the medical sector will propel the organ-on-chip market at an exceptional CAGR of 40.1% during 2018–2025. The market revenue is expected to grow from $11.0 million in 2017 to $163.1 million by 2025. For instance, in 2020, the National Center for Advancing Translational Sciences (NCATS) administered 10 grants through the "Clinical Trials" on a Chip program to support the development of microphysiological and bioengineered models of human organ and tissue systems to improve the success rate of new therapeutics in drug development.

Browse detailed report - Organ-on-Chip Market Analysis and Demand Forecast Report

Furthermore, the Asia-Pacific (APAC) region is also expected to emerge as an eminent user of organ-on-chip products and services in the forthcoming years. This will be on account of the mushrooming healthcare expenditure, surging adoption of advanced technologies in the healthcare sector, and increasing government funding for healthcare research and development (RD) activities in the region. At present, government organizations, such as the National Key Scientific Instrument and Equipment Development Project, China and the Chinese Academy of Sciences, are engaging in research activities for determining the potential of organ-on-chip as a new platform for biological analysis.

Thus, the rising need for drug development and discovery and mounting government support toward the medical sector will facilitate the adoption of organ-on-chip products globally.